Navigation Links
Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
Date:10/26/2007

BERKELEY HEIGHTS, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that Dr. Betsy McCaughey has submitted her resignation from the Company's Board of Directors. Dr. McCaughey has served on the Board since 2001.

"As a noted author and health policy expert, we appreciate Betsy's commitment to mobilizing the response to reduce hospital infections from multiply resistant organisms, along with her increasing involvement in the national political discourse about healthcare reform," said Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer. "On behalf of all Genta Board members, we wish her success in these endeavors, and we are grateful for her years of counsel and service to our Company."

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Brian Korb

The Trout Group

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
(Date:6/24/2017)... ... 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) ... Erie Convention Center on June 8-10. The weekend consisted of many educational ... and scholarship presentations, and professional networking. , On Friday June 9th, PATS ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: